GlobeNewswire

Immunicum AB presenterar prekliniska data från studier med Ilixadencel och DCP-001 vid det 18:e årsmötet för cancerimmunoterapi (CIMT)

Dela

Pressrelease

3 maj 2021

Immunicum AB presenterar prekliniska data från studier med Ilixadencel och DCP-001 vid det 18:e årsmötet för cancerimmunoterapi (CIMT)

Immunicum AB (publ: IMMU.ST) tillkännagav idag publiceringen av sammanfattningar av prekliniska data från bolagets två huvudprogram, ilixadencel och DCP-001. Muntliga presentationer kommer att hållas vid det 18: e årsmötet för cancerimmunoterapi (CIMT), som hålls digitalt den maj 10 - 12 maj 2021. Sammanfattningarna finns nu tillgängliga på mötets webbplats. Presentationerna innehåller uppdaterade prekliniska data gällande kombinationen av ilixadencel med en checkpoint-hämmare riktad mot CTLA4 och nya prekliniska data vad gäller DCP-001s verkningsmekanism och dess kombination med antikroppar som blockerar det framväxande immunterapimålet CD47.

"Vi värdesätter möjligheten att få presentera dessa nya uppmuntrande data som ytterligare bekräftar våra nyskapande angreppssätt för immunterapi", säger Alex Karlsson-Parra, Chief Scientific Officer på Immunicum. ”Resultaten, som publiceras i sammanfattningarna idag, stödjer möjligheten i att kombinera immunprimern ilixadencel med en checkpoint-hämmare och understryker den viktiga interaktionen med patientens egna immunceller genom DCP-001s verkningsmekanism. Båda presentationerna belyser vårt ledarskap när det gäller att utveckla nya cellbaserade terapier mot cancer. ”

Nya data som publiceras idag utökar tidigare data från prekliniska experiment med ilixadencel i kombination med checkpoint-hämmaren anti-CTLA4 i en djurmodell med koloncancer (CT-26). Tidigare data visade att kombinationen av ilixadencel och anti-CTLA4 ledde till fullständig avstötning av tumörer hos 50–80% av de behandlade djuren. Denna effekt drivs huvudsakligen av CD8 + T-celler. I de data som ska presenteras vid CIMT bekräftade karakterisering av CD8 + T-celler från blodprover att kombinationen av ilixadencel och anti-CTLA4-behandling ökade andelen CD8 + T-celler som uttrycker de specifika markörerna NKG2D, CX3CR1 och CD39. Dessa markörer indikerar en avgörande population relaterad till tumörinfiltrerande celler med en 'tumörmatchad' fenotyp som kan attackera cancerceller.

Sammanfattningen som täcker DCP-001 belyser nya prekliniska data för verkningsmekanismen genom vilken DCP-001 kan inducera specifik antitumörimmunitet hos patienternas immunceller. Den prekliniska utvärderingen av DCP-001 blandad med mottagarens immunceller, så kallade mononukleära celler från perifert blod (PBMC), visar en inducerad produktion av olika proinflammatoriska cytokiner och kemokiner hos dessa PBMC. Vidare togs DCP-001 effektivt upp av omogna monocyt-deriverade dendritceller, och blockaden av "ät mig inte" -signalen och det nya immunterapimålet CD47 förbättrade upptagningen av DCP-001. Resultaten antyder att patientens immunceller har en viktig roll vad gäller att utlösa immunsvaret vid DCP-001-vaccination och stödjer det kliniska rationalen för ytterligare kombinationsbehandlingar, inklusive CD47-hämmare.

Sammanfattningen för årsmötet publicerades idag i online-programboken på CIMT-konferensen webbplats och finns tillgänglig här. eTalks kommer att vara tillgängliga för registrerade deltagare på konferensens onlineplattform till och med den 12 juni 2021.

Detaljer om presentationerna är som följer:

Titel: Combining intratumoral administration of inflammatory allogeneic DCs with systemic anti-CTLA-4 treatment leads to tumor eradication and is associated with peripheral expansion of CD8+ effector cells with a “tumor-matched” phenotype

Sammanfattningt #:       A-217

Ämne:                              Terapeutisk vaccination

eTalk:                               eTalk del 1, måndag, 10 maj 2021, 14:00-15:00 (CEST)

Presentatör:                   Alex Karlsson-Parra, Chief Scientific Officer på Immunicum

Titel: CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001

Sammanfattning #:        A-337

Ämne:                             Cellterapi

eTalk:                              eTalk del 2, tisdag, 11 maj 2021; 17:00-18:00 (CEST)

Presentatör:                   Satwinder Kaur Singh, Director of Research på Immunicum

För mer information, vänligen kontakta:

Erik Manting

Chief Executive Officer

Telephone: +31 713 322 627

E-mail: ir@immunicum.com

investerarrelationer

Sijme Zeilemaker

Head of Investor Relations & Corporate Communication

Telephone: +46 8 732 8400

E-mail: ir@immunicum.com

pressfrågor

Eva Mulder and Sophia Hergenhan

Trophic Communications

Telephone: +49 175 222 57 56

E-mail: immu@trophic.eu

Om Immunicum AB (publ)

Immunicum tillämpar sin framstående expertis i dendritcellsbiologi för att utveckla nya, lagringsbara (off-the-shelf), cellbaserade terapier för solida och blodburna tumörer. Med kompletterande terapeutiska angreppssätt i klinisk Fas II-utveckling baserade på intratumoral immunaktivering och canceråterfallsvaccin (relapse vaccine) är bolagets mål att förbättra överlevnad och livskvaliteten för en stor grupp cancerpatienter. Baserat i Sverige och Nederländerna, Immunicum är noterat på Nasdaq Stockholm. www.immunicum.com

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

New Management Appointments in Golar LNG Ltd.13.5.2021 15:05:36 CEST | Press release

The board of Golar LNG Limited ("Golar") is pleased to announce that they have appointed Mr. Karl Fredrik Staubo as the new Chief Executive Officer of the company in their board meeting on 13th May 2021. Mr. Staubo has since May 2020 been the Chief Executive Officer of Golar LNG Partners LP, recently successfully sold to New Fortress Energy. Since September 2020 Mr. Staubo has also been acting as Chief Financial Officer of Golar. Mr. Staubo has a broad shipping/energy background from Clarksons Platou Securities (2010-2018) and Magni Partners (2018-2020). He has a MA (Business Studies and Economics) from the University of Edinburgh. The board has in the same meeting also appointed Mr. Eduardo Maranhao to take over Mr. Staubo’s role as Chief Financial Officer of Golar. Mr. Maranhao has since 2015 been supporting Golar in different functions including as Chief Financial Officer of Golar Power/Hygo Energy Transition Limited until its recent sale to New Fortress Energy. Prior to joining the

Accumulus Synergy Appoint Francisco Nogueira as Chief Executive Officer13.5.2021 15:00:00 CEST | Press release

Accumulus is the first non-profit corporation designed to establish a relationship between technology, policy and collaboration between drug developers, NGOs, academic institutions and government agencies BURLINGAME, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Accumulus Synergy, a non-profit corporation intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, today announced the appointment of Francisco (Frank) Nogueira as the new chief executive officer (CEO). Mr. Nogueira was previously a vice president of Regulatory Affairs at Roche and served as interim CEO at Accumulus since the fall of 2020. Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities. The common-platform approach to data sharing aims to make the regulatory process more eff

Notification on convocation of the Joint Stock Company “Latvijas Gāze” Annual General Meeting of Shareholders13.5.2021 15:00:00 CEST | Press release

The Board of joint stock company “Latvijas Gāze”, registration number: 40003000642, legal address: Aristida Briana iela 6, Riga, LV-1001, Latvia (hereafter – the Company) calls up and announces that Annual General Meeting of Shareholders of the Company will take place on June 15, 2021 at 10.00 at the premises of the Company at Aristida Briana iela 6, Riga, LV-1001, Latvia using electronic means of communication. Agenda: Reports of the Board, the Council and the Audit Committee, and the certified auditor’s opinion.Approval of the Annual Report 2020.Distribution of the profit.Setting of remuneration to the members of the Council and the Audit Committee for the 2020 annual performance.Election of the auditor of the 2020 annual accounts and setting of remuneration to the auditor.Election of the Council and setting of remuneration to the Council. The record date for participation at the Annual General Meeting of Shareholders of the Company is June 7, 2021. Only those persons who are shareho

Vertex Acquires Taxamo to Expand Global Commerce and Compliance Solutions13.5.2021 13:30:00 CEST | Press release

European specialist in tax automation for e-commerce and marketplaces KING OF PRUSSIA, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of tax technology solutions, today announced it has acquired Taxamo, a cloud-based pioneer in tax and payment automation for global e-commerce and marketplaces. Taxamo, headquartered in Ireland, counts many of the leading, high-growth digital service providers among its global customers who rely on its unified platform of integrated capabilities to support indirect tax compliance, with a core focus on online sales, payments, and e-invoicing. “The fabric of today’s global commerce is more connected and complex than ever before,” said Vertex CEO David DeStefano. “Our mission is to enable every business to transact, comply and grow with confidence. We are incredibly excited to bring these new end-to-end solutions to our customers and partners around the world.” Taxamo’s cloud-based so

Results 2021 Annual General Meeting13.5.2021 08:30:00 CEST | Press release

PRESS RELEASE: Amsterdam – 13 May 2021.Intertrust N.V. (“Intertrust”) [Euronext: INTER], a global leader in providing tech-enabled corporate and fund solutions to clients operating and investing in international business, announces that in the Annual General Meeting of 12 May 2021 (2021AGM) the shareholders adopted all voting items on the agenda. At the 2021 AGM a total of 73.59% of the total issued share capital was represented. The results of the votes for each item on the agenda, will be published on our website https://www.intertrustgroup.com/investors/shareholder-information/annual-general-meeting-may-2021/ . Draft minutes of the 2021 AGM will be published no later than three months after the end of the meeting, after which shareholders should have the opportunity to react in the following three months. About Intertrust Intertrust has 4,000+ employees who are dedicated to providing world-leading, specialised administration services to clients in over 30 jurisdictions. This is ampl

Update on Kurdistan Payments13.5.2021 07:51:03 CEST | Press release

Oslo, 13 May 2021 – DNO ASA, the Norwegian oil and gas operator, today reported that Kurdistan’s Minister of Natural Resources has informed the international oil companies operating in the region of an intention to extend the payment period for arrears built up from non-payment of certain invoices in 2019 and 2020. As widely reported, last December the Prime Minister of Kurdistan announced a decision to pay the companies 50 percent of incremental revenue in any month in which Brent prices exceed USD 50 per barrel towards the arrears. The revised terms reduce the payment of the withheld amounts to 20 percent of incremental revenue above USD 50 per barrel. The Minister also advised that all international oil company invoices, including towards withheld amounts, will now be settled within 60 days of receipt. DNO is reviewing its position and will engage with Kurdistan to seek agreement regarding payment terms, interest on the arrears and revised lifting arrangements. – For further informa

Mandalay Resources Corporation Announces Financial Results for the First Quarter of 202113.5.2021 00:05:33 CEST | Press release

TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce its financial results for the quarter March 31, 2021. The Company’s condensed and consolidated interim financial results for the quarter ended March 31, 2021, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. First Quarter 2021 Highlights: Quarterly revenue of $52.6 million; highest since Q2 2016;Adjusted EBITDA of $26.1 million; third highest in Company’s history;Adjusted net income of $5.6 million ($0.06 or C$0.08 per share); andConsolidated net income of $25.5 million ($0.28 or C$0.35 per share). Dominic Duffy, President and CEO of Mandalay, commented: “Mandalay Resources is ple